Skip to main content

Tourmaline Bio, Inc.

TRMLDelisted Oct 28, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001827506

Tourmaline Bio, Inc. was delisted on Oct 28, 2025; its insiders filed their last Form 4 on Oct 28, 2025; 134 institutions reported holding it in 13F filings for Q3 2025, worth $1.03B in total; no superinvestor held it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 2:32 PM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of Tourmaline Bio, Inc., annual
Line itemFY2024FY2023FY2022FY2021
Period endDec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K
ReportedMar 13, 2025Jan 24, 2024Feb 16, 2023Mar 17, 2022
Operating expenses$89.7M$45.4M$76.5M$47.5M
Research and development$67.0M$32.4M$57.0M$34.2M
Selling, general and administrative$22.7M$13.0M$19.5M$13.3M
Operating income-$89.7M-$45.4M-$76.5M-$47.5M
Income tax$0$0$0$0
Net income-$73.2M-$42.1M-$73.9M-$47.8M
EPS, basic$-2.89$-8.87$-1.79–
EPS, diluted$-2.89$-8.87$-1.79–
Weighted shares, basic25.3M4.75M41.2M–
Weighted shares, diluted25.3M4.75M41.2M–

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Tourmaline Bio, Inc., annual
Line itemFY2024FY2023FY2022FY2021
Period endDec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K
ReportedMar 13, 2025Jan 24, 2024Feb 16, 2023Mar 17, 2022
Cash and equivalents$30.5M$140.7M$13.7M$18.6M
Short-term investments––$167.6M$225.4M
Total current assets$268.8M$208.9M$185.6M$246.5M
Property, plant and equipment$55.0K$85.0K$5.35M$4.80M
Total assets$309.0M$210.3M$193.7M$251.4M
Accounts payable$3.58M$1.07M$3.89M$2.56M
Total current liabilities$8.91M$5.00M$11.5M$7.99M
Total liabilities$8.95M$5.25M$13.7M$8.61M
Shareholders' equity$300.1M$205.0M$180.1M$242.8M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Tourmaline Bio, Inc., annual
Line itemFY2024FY2023FY2022FY2021
Period endDec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K
ReportedMar 13, 2025Jan 24, 2024Feb 16, 2023Mar 17, 2022
Operating cash flow-$77.3M-$28.1M-$60.9M-$40.0M
Capital expenditures$9.00K$56.0K$3.04M$2.44M
Free cash flow-$77.3M-$28.1M-$63.9M-$42.4M
Depreciation and amortization––$1.38M$623.0K
Stock-based compensation$6.59M$5.77M$11.2M$3.78M
Share buybacks$4.00K–––
Investing cash flow-$194.3M$3.84M$55.7M-$96.4M
Financing cash flow$161.3M$156.7M$242.0K$137.4M
Net change in cash-$110.2M$132.5M-$4.94M$1.02M

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Tourmaline Bio, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Aug 1, 202525.7M+0.2%SEC
Apr 25, 202525.7M+0.2%SEC
Mar 7, 202525.7M+0.2%SEC
Nov 1, 202425.6M+26.1%SEC
Aug 2, 202425.6M−40.0%SEC
May 10, 202425.6M−39.2%SEC
Mar 15, 202425.6M−39.0%SEC
Nov 10, 202320.3M−51.3%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.